Cargando…
The complex relationship between body mass index and response to immune checkpoint inhibition in metastatic melanoma patients
Despite major improvements in combatting metastatic melanoma since the advent of immunotherapy, the overall survival for patients with advanced disease remains low. Recently, there is a growing number of reports supporting an “obesity paradox,” in which patients who are overweight or mildly obese ma...
Autores principales: | Donnelly, Douglas, Bajaj, Shirin, Yu, Jaehong, Hsu, Miles, Balar, Arjun, Pavlick, Anna, Weber, Jeffrey, Osman, Iman, Zhong, Judy |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6700794/ https://www.ncbi.nlm.nih.gov/pubmed/31426863 http://dx.doi.org/10.1186/s40425-019-0699-5 |
Ejemplares similares
-
Bacteroides vulgatus and Bacteroides dorei predict immune-related adverse events in immune checkpoint blockade treatment of metastatic melanoma
por: Usyk, Mykhaylo, et al.
Publicado: (2021) -
Checkpoint inhibition immunotherapy for advanced local and systemic conjunctival melanoma: a clinical case series
por: Finger, Paul T., et al.
Publicado: (2019) -
Baseline prognostic nutritional index and changes in pretreatment body mass index associate with immunotherapy response in patients with advanced cancer
por: Johannet, Paul, et al.
Publicado: (2020) -
Survival after checkpoint inhibitors for metastatic acral, mucosal and uveal melanoma
por: Klemen, Nicholas D., et al.
Publicado: (2020) -
Pembrolizumab in the treatment of locally advanced or metastatic urothelial carcinoma: clinical trial evidence and experience
por: Crist, Michael, et al.
Publicado: (2019)